Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology at Hannover Medical School, shared an article by Choong-kun Lee, et al. on X:
“RW Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for HCC in Asia-Pacific.
- 1,141 pts, 55.1% 2nd line.
- mPFS 2.9; mOS: 8 mo.
- Lenva better compared to Sora, TKI plus ICI promising.
- IMbrave 251 phase-3 awaited!
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries.
Authors: Choong-kun Lee, et al.
